

INDIA

## Bharat Heavy Electricals

7 April 2008

**BHEL IN** **Outperform**

Stock price as of 04 Apr 08	Rs	1,634.10
12-month target	Rs	2,227.00
Upside/downside	%	+36.3
Valuation	Rs	2,227.00
- PER		

GICS sector		capital goods
Market cap	Rs m	799,925
30-day avg turnover	US\$m	88.4
Market cap	US\$m	20,028
Number shares on issue	m	489.5

### Investment fundamentals

Year end 31 Mar		2007A	2008E	2009E	2010E
Total revenue	bn	176.1	202.7	265.0	351.4
EBITDA	bn	36.2	41.0	57.2	85.6
EBITDA growth	%	40.2	13.0	39.7	49.7
Recurring profit	bn	37.4	44.0	61.6	91.8
Reported profit	bn	24.1	28.2	40.7	60.6
Adjusted profit	bn	24.1	28.2	40.7	60.6
EPS rep	Rs	49.33	57.53	83.06	123.73
EPS rep growth	%	43.8	16.6	44.4	49.0
EPS adj	Rs	49.33	57.53	83.06	123.73
EPS adj growth	%	43.8	16.6	44.4	49.0
PE rep	x	33.1	28.4	19.7	13.2
PE adj	x	33.1	28.4	19.7	13.2
Total DPS	Rs	14.15	13.95	20.14	30.01
Total div yield	%	0.9	0.9	1.2	1.8
ROA	%	16.2	14.8	17.0	20.0
ROE	%	30.0	28.6	32.6	37.2
EV/EBITDA	x	20.1	17.7	12.7	8.5
Net debt/equity	%	-65.1	-66.9	-65.5	-63.2
Price/book	x	9.1	7.3	5.7	4.3

### BHEL IN rel SENSEX performance, & rec history



Source: Datastream, Macquarie Research, April 2008 (all figures in INR unless noted)

### Analysts

**Indrajeetsingh Bhatia**  
91 22 6653 3166 [indrajeet.bhatia@macquarie.com](mailto:indrajeet.bhatia@macquarie.com)

**Somesh Agarwal**  
91 22 6653 3064 [somesh.agarwal@macquarie.com](mailto:somesh.agarwal@macquarie.com)

## Execution worries look overdone

### Event

- Bharat Heavy Electricals' (BHEL) provisional numbers for FY3/08 disappointed on account of a delay in the execution of projects and one-time charges. We are cutting our target price to Rs2,227 from Rs2,751. We believe the price correction of 22% over the last week has overcompensated for the earnings cut. We reaffirm our Outperform recommendation on the stock.

### Impact

- **Extreme pessimism on execution unwarranted:** In a complete turnaround, concerns on BHEL's order inflow/backlog have taken a back seat, and we believe execution ramp-up is the key concern for the stock. We expect execution to improve in FY3/10 for the following reasons.
  - ⇒ **Capacity expansion to boost growth:** We believe the company will begin to benefit from the capacity expansion to 10GW that was achieved in Dec-07 and the further expansion to 15GW expected by Dec-09.
  - ⇒ **Order book matures to deliver growth:** A bulk of the order book comprises orders received in FY3/08, which typically do not contribute to revenues for three quarters, as they are in initial stages of design and engineering.
- **Order backlog/inflow remains robust:** The company has reported FY3/08 order inflow and order backlog growth of 41% and 56%, respectively. Management has guided to Rs400–500bn of further order inflow for FY3/09. A further boost to the order book could come from negotiated orders for super-critical equipment that we believe could be placed by the government.
- **Stock building in the worst-case scenario for execution and growth:** We expect the execution rate will decline in FY3/09 to its lowest level in many years and then see a rebound in FY3/10. Even at a lower execution rate, we believe the company is set to deliver 47% earnings growth over FY3/08–10, and with visibility for growth up to FY3/12 based on the projected order backlog to end-FY3/10. The current price builds in 0% growth in order inflow beyond FY3/09.

### Earnings revision

- We are lowering our FY3/09–10 earnings estimates by 8–10%, based on lower top-line expectations.

### Price catalyst

- 12-month price target: Rs2,227.00 based on a PER methodology.
- Catalyst: Clarity emerging on execution would be the most critical trigger

### Action and recommendation

- We have lowered our target price to Rs2,227, based on 18x FY3/10E earnings, to factor in the earnings revision and a lower PER. The multiple is supported by our DCF analysis and strong earnings growth beyond FY3/10. We reaffirm our Outperform rating on the stock.

Please refer to the important disclosures and analyst certification on inside back cover of this document, or on our website [www.macquarie.com.au/research/disclosures](http://www.macquarie.com.au/research/disclosures).

## FY3/08 numbers disappoint due to lower top line

- **FY3/08 top line below expectations, raising concerns on execution:** BHEL reported provisional FY3/08 revenue numbers of Rs216bn, 9% below our expectations. Part of the disappointment was on account of a delay in the commissioning of several power projects to Q1 FY3/09 from Q4 FY3/08. The bigger issue, in our view, remains the short supplies of spares, such as forgings, and the balance of plant equipment. The shortage of spares should continue to pressure growth in FY3/09/10 despite a huge order backlog.
- **Bottom-line disappointment partly explained by provisions:** Provisional net profit for FY3/08 came in at Rs28.2bn, 15% below our expectation. Apart from a shortfall in the top line, two provisions added to the shortfall (when these provisions are removed, FY3/08 earnings were only 7% below our expectation).
  - ⇒ **Provisioning of Rs2bn for wage revision:** Based on the pay commission report, the company took a provision in 4Q FY3/08 of Rs2bn for wage escalation. This new provisioning takes into account a possible 40% salary hike vs company's initial 25% hike assumption. Following this provision, we do not believe the company will be required to increase staff costs significantly in FY3/09.
  - ⇒ **Write-back of provisions pushed to FY3/09:** BHEL has provided for projects under execution. However, on account of the delayed commissioning of several of these projects, which are recurring in nature, Rs2bn of the provision has been delayed to FY3/09.

## We reduce earning estimates because of the execution delays

- **Guidance for FY3/09 revenue growth is in the range of 16–25%:** BHEL has guided for FY3/09 revenues in the range of Rs250–Rs270bn. Historically, the company has beaten the top end of the guidance; even in FY3/08 the company delivered revenue 3% ahead of the top end of guidance.
- **Cutting FY3/09 and FY3/10 revenue numbers by 8%:** We are lowering our FY3/09 and FY3/10 top-line estimates by 7% and 8%, respectively. Our numbers are coming down despite the fact that the order backlog of Rs855bn for end-FY3/08 is higher than our estimate.
- **Earnings cut by 8–10%:** We are lowering our FY3/09 and FY3/10 earnings estimates by 8–10% to factor in the lower top-line growth by 8%.

**Fig 1 Earnings lowered by 8–10%**


	FY3/09E		FY3/10E		Revision	
	old	new	old	new	09E	10E
Net Revenues	281,757	259,852	374,282	344,489	-8%	-8%
EBITDA	62,123	57,196	94,126	85,601	-8%	-9%
Net Income	44,246	40,661	67,342	60,569	-8%	-10%
EPS	90.4	83.1	137.6	123.7	-8%	-10%

Source: Macquarie Research, April 2008

## Revised numbers build in a pessimistic execution rate

- **Execution slips:** The execution cycle, defined as sales as a percent of the order backlog at the beginning of the year, has come off significantly, falling from 61% in FY3/03 to an all-time low of 39% in FY3/08. Our projected top-line number for FY3/09 builds in a further decline in the execution rate to 33% (which we see improving to 36% in FY3/10).
- **Execution to improve beyond FY3/10:** We believe the execution rate will fall in FY3/09 to its lowest rate in many years, although we expect it to improve in FY3/10. Our key arguments are as follows.
  - ⇒ Revenue growth in FY3/09 should not match the FY3/08 order backlog, as the bulk of the orders have been received through FY3/08. Typically, new order revenues will not be booked for the first two to three quarters as the project undergoes the initial design and engineering phase. Moreover, we note that revenue booked in the initial phase is of low margin.
  - ⇒ In FY3/10, we expect the initial mobilisation period for the current order backlog will be completed and significant revenues from the projects will be booked, leading to a rebound in the execution rate.

**Fig 2 We expect the execution rate to slip further in FY3/09 before rebounding in FY3/10**




Source: Macquarie Research, April 2008

**Valuation: Reducing 12-month price target to Rs2,227**


- We are lowering our 12-month target price to Rs2,227, based on 18x FY3/10E earnings, from Rs2,751, or a 19% cut. We have also lowered our target one-year forward multiple by 10% to factor in the risk of execution ramp-up.
- **Earnings visibility beyond FY3/10 and balance sheet strength support the target multiple:**  
 We project an order coverage ratio (order backlog/trailing 12-months revenues) for FY3/10 of 3.0x despite our assumption of a decline in order inflow in FY3/09 and meagre 2% growth in FY3/10. We expect order backlog coverage of 3.0x in FY3/10 provides visibility for top-line growth of around 25% for another two to three years. Moreover, we believe the strength of the company's balance sheet is underappreciated. BHEL has net cash of Rs150ps on its books, with net debt to equity of -0.7. The company generates free cashflow and ROE of 30%.

**Fig 3 Growth visibility sustained beyond FY3/10**



Source: Macquarie Research, April 2008

**Fig 4 1-yr forward P/E multiple below 20x**



Source: Macquarie Research, April 2008

- **Multiple justified by DCF:** Our target price multiple is also based on the implied multiple from our DCF analysis for BHEL. Our implied value for DCF is Rs2,231. Our key assumptions for the DCF follow.
  - ⇒ **Order inflow growth to remain muted in FY3/09 and FY3/10:** We have built in a decline in order inflow of 9% in FY3/09 and growth of 2% in FY3/10. We are assuming a pickup in order inflow in FY3/11 on the back of the government's Twelfth Five-Year Plan (FY3/12–17).
  - ⇒ **Execution rates to improve gradually:** We are assuming an execution rate in the terminal year (FY3/14) of 44%. We expect execution rates will improve as order backlog coverage declines over interim period (FY3/10-14) to a more manageable 2.5 and further capacity expansion taken up by the company beyond FY3/10.
  - ⇒ **Terminal margins of 18%:** We expect margins to settle at 18%, much below peak margins achieved in FY3/10. Assuming a terminal margin of 16%, the DCF target would fall by 5%.
  - ⇒ **Terminal year of FY3/14 and growth rate of 5%:** We have assumed the top line will decelerate significantly from 33% in FY3/10 to 5% in FY3/14. This assumption builds in a market-share loss to competition. Moreover, 5% terminal growth builds in a further loss of market share, as the government projects power demand growth of around 7% beyond FY3/14.
  - ⇒ **ROE to decline to 17% in terminal year:** Our assumptions build ROE to decline from peak of 33% in FY3/10 to 17% in terminal year.

Fig 5 BHEL – Discounted cashflow

Rs m	FY07	FY08E	FY09E	FY10E	FY11E	FY12E	FY13E	FY14E	Perpetuity
Order Inflow	356,430	501,274	455,324	463,710	535,924	588,113	639,425	678,896	
Growth	88%	41%	-9%	2%	16%	10%	9%	6%	
Order Book	550,000	855,000	1,027,838	1,117,053	1,220,029	1,293,862	1,357,844	1,432,525	
Order Book Coverage Rate	3.2	4.3	4.0	3.2	3.5	3.0	2.6	2.5	
Revenues	172,375	198,693	259,852	344,489	432,948	514,280	575,443	604,215	
Growth	29%	15%	31%	33%	26%	19%	12%	5%	
Execution Rate	46%	36%	30%	34%	39%	42%	44%	44%	
EBITDA	36,248	40,953	57,196	85,601	98,923	107,220	108,463	102,717	
EBITDA Margin	21.0%	20.6%	22.0%	24.8%	22.8%	20.8%	18.8%	17.0%	
NOPAT	26,872	31,254	44,118	64,555	73,346	84,265	89,929	90,321	
<b>FCF-Equity</b>	<b>18,202</b>	<b>23,955</b>	<b>28,554</b>	<b>40,365</b>	<b>68,214</b>	<b>63,510</b>	<b>79,507</b>	<b>112,676</b>	<b>1,671,125</b>
Sum of PV of FCF (Equity Value)			1,074,304						
Shares			490						
<b>Equity Value per Share (Ps) - bop</b>			<b>2,195</b>						
Implied FY10 multiple			17.7						
Growth Rate in Perpetuity			5.0%						
Discount Rate (Cost of Equity)			13.0%						

Source: Macquarie Research, April 2008

- **Price builds in worst-case scenario for growth:** The stock has corrected 22% in the last week on concerns on execution. We believe the price correction has more than compensated for the earnings downgrades. The current price builds in 0% growth in order inflow beyond FY3/10 until the terminal year and a terminal growth rate of 0%. Despite no order inflow growth, BHEL should deliver growth in the interim period, as execution improves on back of increasing capacity. The company has stated that it wants to increase capacity to 20GW by FY3/12.

**Bharat Heavy Electricals (BHEL IN, Outperform, Target price: Rs2,227.00)**

Quarterly Results					Profit & Loss						
	3Q/08A	4Q/08E	1Q/09E	2Q/09E		2007A	2008E	2009E	2010E		
<b>Revenue</b>	m	50,667	50,667	66,262	66,262	<b>Revenue</b>	m	176,143	202,667	265,049	351,379
<b>Gross Profit</b>	m	14,113	14,113	18,755	18,755	<b>Gross Profit</b>	m	51,012	56,451	75,019	106,097
Cost of Goods Sold	m	36,554	36,554	47,508	47,508	Cost of Goods Sold	m	125,131	146,217	190,030	245,282
<b>EBITDA</b>	m	10,238	10,238	14,299	14,299	<b>EBITDA</b>	m	36,248	40,953	57,196	85,601
Depreciation	m	774	774	864	864	Depreciation	m	2,730	3,094	3,457	3,986
Amortisation of Goodwill	m	0	0	0	0	Amortisation of Goodwill	m	0	0	0	0
Other Amortisation	m	0	0	0	0	Other Amortisation	m	0	0	0	0
<b>EBIT</b>	m	9,465	9,465	13,435	13,435	<b>EBIT</b>	m	33,518	37,858	53,740	81,615
Net Interest Income	m	1,126	1,126	1,317	1,317	Net Interest Income	m	2,748	4,502	5,269	6,711
Associates	m	0	0	0	0	Associates	m	0	0	0	0
Exceptionals	m	0	0	0	0	Exceptionals	m	0	0	0	0
Forex Gains / Losses	m	0	0	0	0	Forex Gains / Losses	m	0	0	0	0
Other Pre-Tax Income	m	397	397	650	650	Other Pre-Tax Income	m	1,094	1,590	2,599	3,445
<b>Pre-Tax Profit</b>	m	10,988	10,988	15,402	15,402	<b>Pre-Tax Profit</b>	m	37,361	43,950	61,607	91,771
Tax Expense	m	-3,948	-3,948	-5,237	-5,237	Tax Expense	m	-13,214	-15,790	-20,947	-31,202
<b>Net Profit</b>	m	7,040	7,040	10,165	10,165	<b>Net Profit</b>	m	24,147	28,160	40,661	60,569
Minority Interests	m	0	0	0	0	Minority Interests	m	0	0	0	0
<b>Reported Earnings</b>	m	7,040	7,040	10,165	10,165	<b>Reported Earnings</b>	m	24,147	28,160	40,661	60,569
<b>Adjusted Earnings</b>	m	7,040	7,040	10,165	10,165	<b>Adjusted Earnings</b>	m	24,147	28,160	40,661	60,569
EPS (rep)		14.38	14.38	20.77	20.77	EPS (rep)		49.33	57.53	83.06	123.73
EPS (adj)		14.38	14.38	20.77	20.77	EPS (adj)		49.33	57.53	83.06	123.73
EPS Growth yoy (adj)	%	16.6	16.6	44.4	44.4	EPS Growth (adj)	%	43.8	16.6	44.4	49.0
						PE (rep)	x	33.1	28.4	19.7	13.2
						PE (adj)	x	33.1	28.4	19.7	13.2
EBITDA Margin	%	20.2	20.2	21.6	21.6	Total DPS		14.15	13.95	20.14	30.01
EBIT Margin	%	18.7	18.7	20.3	20.3	Total Div Yield	%	0.9	0.9	1.2	1.8
Earnings Split	%	25.0	25.0	25.0	25.0	Weighted Average Shares	m	490	490	490	490
Revenue Growth	%	15.1	15.1	30.8	30.8	Period End Shares	m	490	490	490	490
EBIT Growth	%	12.9	12.9	41.9	41.9						
Profit and Loss Ratios					Cashflow Analysis						
	2007A	2008E	2009E	2010E		2007A	2008E	2009E	2010E		
Revenue Growth	%	29.0	15.1	30.8	32.6	<b>EBITDA</b>	m	36,248	40,953	57,196	85,601
EBITDA Growth	%	40.2	13.0	39.7	49.7	Tax Paid	m	-13,214	-15,790	-20,947	-31,202
EBIT Growth	%	43.2	12.9	41.9	51.9	Chgs in Working Cap	m	7,814	-799	-6,563	-15,190
Gross Profit Margin	%	29.0	27.9	28.3	30.2	Net Interest Paid	m	2,748	4,502	5,269	6,711
EBITDA Margin	%	20.6	20.2	21.6	24.4	Other	m	-82	0	0	0
EBIT Margin	%	19.0	18.7	20.3	23.2	<b>Operating Cashflow</b>	m	33,514	28,865	34,956	45,920
Net Profit Margin	%	13.7	13.9	15.3	17.2	Acquisitions	m	0	0	0	0
Payout Ratio	%	28.7	24.3	24.3	24.3	Capex	m	-3,887	-7,793	-9,000	-9,000
EV/EBITDA	x	20.1	17.7	12.7	8.5	Asset Sales	m	0	0	0	0
EV/EBIT	x	21.7	19.2	13.5	8.9	Other	m	1,094	1,590	2,599	3,445
<b>Balance Sheet Ratios</b>					<b>Investing Cashflow</b>	m	-2,793	-6,203	-6,401	-5,555	
ROE	%	30.0	28.6	32.6	37.2	Dividend (Ordinary)	m	-6,925	-6,829	-9,861	-14,689
ROA	%	16.2	14.8	17.0	20.0	Equity Raised	m	0	0	0	0
ROIC	%	58.1	79.0	98.0	111.5	Debt Movements	m	-4,689	1,000	0	0
Net Debt/Equity	%	-65.1	-66.9	-65.5	-63.2	Other	m	-2,353	-0	0	0
Interest Cover	x	nmf	nmf	nmf	nmf	<b>Financing Cashflow</b>	m	-13,967	-5,829	-9,861	-14,689
Price/Book	x	9.1	7.3	5.7	4.3	<b>Net Chg in Cash/Debt</b>	m	16,749	16,833	18,694	25,676
Book Value per Share		179.5	223.1	286.0	379.7						
					Balance Sheet						
	2007A	2008E	2009E	2010E		2007A	2008E	2009E	2010E		
Cash	m	58,089	74,922	93,616	119,292	Cash	m	58,089	74,922	93,616	119,292
Receivables	m	96,958	111,762	146,162	193,769	Receivables	m	96,958	111,762	146,162	193,769
Inventories	m	42,177	48,616	63,580	84,289	Inventories	m	42,177	48,616	63,580	84,289
Investments	m	83	83	83	83	Investments	m	83	83	83	83
Fixed Assets	m	12,913	17,611	23,154	28,169	Fixed Assets	m	12,913	17,611	23,154	28,169
Intangibles	m	0	0	0	0	Intangibles	m	0	0	0	0
Other Assets	m	22,757	24,804	29,560	36,143	Other Assets	m	22,757	24,804	29,560	36,143
<b>Total Assets</b>	m	232,977	277,798	356,157	461,745	<b>Total Assets</b>	m	232,977	277,798	356,157	461,745
Payables	m	35,390	57,880	105,438	165,146	Payables	m	35,390	57,880	105,438	165,146
Short Term Debt	m	0	0	0	0	Short Term Debt	m	0	0	0	0
Long Term Debt	m	893	1,893	1,893	1,893	Long Term Debt	m	893	1,893	1,893	1,893
Provisions	m	25,222	25,222	25,222	25,222	Provisions	m	25,222	25,222	25,222	25,222
Other Liabilities	m	83,589	83,589	83,589	83,589	Other Liabilities	m	83,589	83,589	83,589	83,589
<b>Total Liabilities</b>	m	145,094	168,585	216,143	275,851	<b>Total Liabilities</b>	m	145,094	168,585	216,143	275,851
Shareholders' Funds	m	87,883	109,214	140,014	185,894	Shareholders' Funds	m	87,883	109,214	140,014	185,894
Minority Interests	m	0	0	0	0	Minority Interests	m	0	0	0	0
Other	m	0	0	0	0	Other	m	0	0	0	0
<b>Total S/H Equity</b>	m	87,883	109,214	140,014	185,894	<b>Total S/H Equity</b>	m	87,883	109,214	140,014	185,894
<b>Total Liab &amp; S/H Funds</b>	m	232,977	277,798	356,157	461,745	<b>Total Liab &amp; S/H Funds</b>	m	232,977	277,798	356,157	461,745

All figures in INR unless noted.

Source: Macquarie Research, April 2008

## Important disclosures:

Recommendation definitions	Volatility index definition*	Financial definitions
<p><b>Macquarie - Australia/New Zealand</b>            Outperform – return &gt;5% in excess of benchmark return (&gt;2.5% in excess for listed property trusts)            Neutral – return within 5% of benchmark return (within 2.5% for listed property trusts)            Underperform – return &gt;5% below benchmark return (&gt;2.5% below for listed property trusts)</p> <p><b>Macquarie - Asia</b>            Outperform – expected return &gt;+10%            Neutral – expected return from -10% to +10%            Underperform – expected return &lt;-10%</p> <p><b>Macquarie First South - South Africa</b>            Outperform – expected return &gt;+10%            Neutral – expected return from -10% to +10%            Underperform – expected return &lt;-10%</p> <p><b>Macquarie - Canada</b>            Outperform – return &gt;5% in excess of benchmark return            Neutral – return within 5% of benchmark return            Underperform – return &gt;5% below benchmark return</p> <p><b>Macquarie - USA</b>            Outperform (Buy) – return &gt;5% in excess of benchmark return            Neutral (Hold) – return within 5% of benchmark return            Underperform (Sell) – return &gt;5% below benchmark return</p> <p><b>Recommendations</b> – 12 months</p> <p><b>Note:</b> Quant recommendations may differ from Fundamental Analyst recommendations</p>	<p>This is calculated from the volatility of historic price movements.</p> <p><b>Very high–highest risk</b> – Stock should be expected to move up or down 60–100% in a year – investors should be aware this stock is highly speculative.</p> <p><b>High</b> – stock should be expected to move up or down at least 40–60% in a year – investors should be aware this stock could be speculative.</p> <p><b>Medium</b> – stock should be expected to move up or down at least 30–40% in a year.</p> <p><b>Low–medium</b> – stock should be expected to move up or down at least 25–30% in a year.</p> <p><b>Low</b> – stock should be expected to move up or down at least 15–25% in a year.            * Applicable to Australian/NZ stocks only</p>	<p>All "Adjusted" data items have had the following adjustments made:            Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives &amp; hedging, IFRS impairments &amp; IFRS interest expense            Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends &amp; minority interests</p> <p><b>EPS</b> = adjusted net profit / <i>efpowa</i>*  <b>ROA</b> = adjusted ebit / average total assets  <b>ROA Banks/Insurance</b> = adjusted net profit / average total assets  <b>ROE</b> = adjusted net profit / average shareholders funds  <b>Gross cashflow</b> = adjusted net profit + depreciation            *equivalent fully paid ordinary weighted average number of shares</p> <p>All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).</p>

## Recommendation proportions – For quarter ending 31 March 2008

	AU/NZ	Asia	RSA	USA	CA
Outperform	38.95%	70.56%	64.52%	50.00%	69.72%
Neutral	47.37%	16.32%	27.42%	39.47%	26.06%
Underperform	13.68%	13.12%	8.06%	10.53%	4.22%


**Analyst Certification:** The views expressed in this research accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst principally responsible for the preparation of this research receives compensation based on overall revenues of Macquarie Group Ltd ABN 94 122 169 279 (AFSL No. 318062) ('Macquarie') and its related entities ('the Macquarie group') and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

**Disclaimers:** Macquarie Capital Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Securities Ltd; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Capital Securities (NZ) Ltd; and Macquarie First South Securities (Pty) Limited are not authorised deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or Macquarie Group Limited 94 122 169 279 (MGL). Neither MGL nor MBL guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. This research has been prepared for the general use of the wholesale clients of the Macquarie group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader. Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research.

**Other Disclaimers:** In Canada, securities research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd, a participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. Macquarie Capital Markets North America Ltd., which is a registered broker-dealer and member of FINRA, accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd in the United States and to US persons and any person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd should do so with Macquarie Capital Markets North America Ltd. Securities research is issued and distributed by Macquarie Capital Securities (Australia) Ltd (AFSL No. 238947) in Australia, a participating organisation of the Australian Securities Exchange; Macquarie Capital Securities (NZ) Ltd in New Zealand, a licensed sharebroker and New Zealand Exchange Firm; Macquarie Capital (Europe) Ltd in the United Kingdom, which is authorised and regulated by the Financial Services Authority (No. 193905); Macquarie Capital Securities Ltd in Hong Kong, which is licensed and regulated by the Securities and Futures Commission; Macquarie Capital Securities (Japan) Limited in Japan, a member of the Tokyo Stock Exchange, Inc., Osaka Securities Exchange Co. Ltd, and JASDAQ Securities Exchange, Inc. (Financial Instruments Firm, Kanto Financial Bureau (Kin-sho) No. 231, a member of Japan securities Dealers Association and Financial Futures Association of Japan); Macquarie First South Securities (Pty) Limited in South Africa, a member of the JSE Limited and in Singapore, Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services licence holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. Clients should contact analysts at, and execute transactions through, a Macquarie group entity in their home jurisdiction unless governing law permits otherwise. Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA, accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. The information contained in this document is confidential. If you are not the intended recipient, you must not disclose or use the information in this document in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. Macquarie has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FSA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Disclosures with respect to the issuers, if any, mentioned in this research are available at [www.macquarie.com/research/disclosures](http://www.macquarie.com/research/disclosures). © Macquarie Group

<b>Auckland</b> Tel: (649) 377 6433	<b>Bangkok</b> Tel: (662) 694 7999	<b>Calgary</b> Tel: (1 403) 218 6650	<b>Hong Kong</b> Tel: (852) 2823 3588	<b>Jakarta</b> Tel: (62 21) 515 1818	<b>Johannesburg</b> Tel: (27 11) 343 2258	<b>Kuala Lumpur</b> Tel: (60 3) 2059 8833
<b>London</b> Tel: (44 20) 7065 2000	<b>Manila</b> Tel: (63 2) 857 0888	<b>Melbourne</b> Tel: (613) 9635 8139	<b>Montreal</b> Tel: (1 514) 925 2850	<b>Mumbai</b> Tel: (91 22) 6653 3000	<b>Perth</b> Tel: (618) 9224 0888	<b>Seoul</b> Tel: (82 2) 3705 8500
<b>Shanghai</b> Tel: (86 21) 6841 3355	<b>Singapore</b> Tel: (65) 6231 1111	<b>Sydney</b> Tel: (612) 8232 9555	<b>Taipei</b> Tel: (886 2) 2734 7500	<b>Tokyo</b> Tel: (81 3) 3512 7900	<b>Toronto</b> Tel: (1 416) 848 3500	<b>New York</b> Tel: (1 212) 231 2500

Available to clients on the world wide web at [www.macquarie.com/research](http://www.macquarie.com/research) and through Thomson Financial, FactSet, Reuters and Bloomberg.



## Research

### Head of Equity Research

Stephen O'Sullivan (852) 2823 3566

### Automobiles/Auto Parts

Claire Ding (China) (852) 2823 3578  
 Deepak Jain (India) (9122) 6653 3157  
 Kenneth Yap (Indonesia) (6221) 515 7343  
 Toshisuke Hayami (Japan) (813) 3512 7873  
 Eunsook Kwak (Korea) (822) 3705 8644  
 Linda Huang (Taiwan) (8862) 2734 7539

### Banks and Non-Bank Financials

Ismael Pili (Asia) (65) 6231 2840  
 Nick Lord (Asia, China, Hong Kong) (852) 2823 4774  
 Seshadri Sen (India) (9122) 6653 3053  
 Young Chung Mok (Korea) (822) 3705 8668  
 Chin Seng Tay (Malaysia, S'pore) (65) 6231 2837  
 Matthew Smith (Taiwan) (8862) 2734 7514  
 Alastair Macdonald (Thailand) (662) 694 7741

### Chemicals/Textiles

Scott Weaver (Taiwan) (8862) 2734 7512  
 Jal Irani (India) (9122) 6653 3040  
 Christina Lee (Korea) (822) 3705 8670  
 Sunaina Dhanuka (Malaysia) (603) 2059 8993

### Conglomerates

Gary Ping (Asia) (852) 2823 3557  
 Leah Jiang (China) (8621) 2412 9020  
 Kenneth Yap (Indonesia) (6221) 515 7343  
 Ashwin Sanketh (Singapore) (65) 6231 2830

### Consumer

Nicolas Wang (China) (8621) 2412 9018  
 Jessie Qian (China, Hong Kong) (852) 2823 3568  
 Unmesh Sharma (India) (9122) 6653 3042  
 Sarina Lesmina (Indonesia) (6221) 515 7339  
 Duane Sandberg (Japan) (813) 3512 7867  
 Heather Kang (Korea) (822) 3705 8677  
 HongSuk Na (Korea) (822) 3705 8678  
 Woochang Chung (Korea) (822) 3705 8667  
 Edward Ong (Malaysia) (603) 2059 8982  
 Alex Pomento (Philippines) (632) 857 0899  
 Linda Huang (Taiwan) (8862) 2734 7539

### Custom Products

Patrick Hansen (Japan) (813) 3512 7876  
 Tsumugi Akiba (Japan) (813) 3512 7560

### Emerging Leaders

Hui-Lui Ko (China) (852) 2823 4704  
 Madhur Rao (India) (9122) 6653 3047  
 Robert Burghart (Japan) (813) 3512 7853  
 Heather Kang (Korea) (822) 3705 8677  
 Woochang Chung (Korea) (822) 3705 8667  
 Nadine Javellana (Philippines) (632) 857 0890  
 Scott Weaver (Taiwan) (8862) 2734 7512

### Industrials

Bin Liu (China) (8621) 2412 9006  
 Inderjeetsingh Bhatia (India) (9122) 6653 3166  
 Christopher Cintavey (Japan) (813) 3512 7432  
 Janet Lewis (Japan) (813) 3512 7475  
 Daniel Yang (Korea) (822) 3705 8658  
 Sunaina Dhanuka (Malaysia) (603) 2059 8993

### Insurance

Makarim Salman (Japan) (813) 3512 7421

### Media

Jessie Qian (China, Hong Kong) (852) 2823 3568  
 Shubham Majumder (India) (9122) 6653 3049  
 Prem Jearajasingam (Malaysia) (603) 2059 8989  
 Alex Pomento (Philippines) (632) 857 0899

### Metals and Mining

Simon Francis (Asia, China) (852) 2823 3590  
 Laban Yu (China) (852) 2823 3575  
 YeeMan Chin (China) (852) 2823 3562  
 Rakesh Arora (India) (9122) 6653 3054  
 Adam Worthington (Indonesia) (6221) 515 7338  
 Polina Diyachkina (Japan) (813) 3512 7886  
 Christina Lee (Korea) (822) 3705 8670  
 Amornrat Cheevavichawalkul (Thai) (662) 694 7829

### Oil and Gas

David Johnson (Asia, China) (852) 2823 4691  
 Scott Weaver (Taiwan) (8862) 2734 7512  
 Jal Irani (India) (9122) 6653 3040  
 Christina Lee (Korea) (822) 3705 8670  
 Edward Ong (Malaysia) (603) 2059 8982  
 Sunaina Dhanuka (Malaysia) (603) 2059 8993  
 Ashwin Sanketh (Singapore) (65) 6231 2830  
 Trevor Buchinski (Thailand) (662) 694 7728

### Pharmaceuticals

Shubham Majumder (India) (9122) 6653 3049  
 Naomi Kumagai (Japan) (813) 3512 7474  
 Christina Lee (Korea) (822) 3705 8670

### Property

Matt Nacard (Asia) (852) 2823 4731  
 Eva Lee (China, Hong Kong) (852) 2823 3573  
 Corinne Jian (China) (852) 2823 4077  
 Chang Han Joo (Japan) (813) 3512 7885  
 Hiroshi Okubo (Japan) (813) 3512 7433  
 Tuck Yin Soong (Singapore) (65) 6231 2838  
 Elaine Cheong (Singapore) (65) 6231 2839  
 Patti Tomaitrichit (Thailand) (662) 694 7727

### Technology

Warren Lau (Asia) (852) 2823 3592  
 Andrew Lin (China, Hong Kong) (852) 2823 3563  
 Suveer Chainani (India) (9122) 6653 3045  
 Damian Thong (Japan) (813) 3512 7877  
 David Gibson (Japan) (813) 3512 7880  
 George Chang (Japan) (813) 3512 7854  
 Yoshihiro Shimada (Japan) (813) 3512 7862  
 Do Hoon Lee (Korea) (822) 3705 8641  
 Michael Bang (Korea) (822) 3705 8659  
 Patrick Yau (Singapore) (65) 6231 2835  
 Andy Kung (Taiwan) (8862) 2734 7534  
 Chia-Lin Lu (Taiwan) (8862) 2734 7526  
 Daniel Chang (Taiwan) (8862) 2734 7516  
 James Chiu (Taiwan) (8862) 2734 7517  
 Nicholas Teo (Taiwan) (8862) 2734 7523

### Telecoms

Tim Smart (Asia, China) (852) 2823 3565  
 Shubham Majumder (India) (9122) 6653 3049  
 Kenneth Yap (Indonesia) (6221) 515 7343  
 Nathan Ramler (Japan) (813) 3512 7875  
 Prem Jearajasingam (Malaysia) (603) 2059 8989  
 Ramakrishna Maruvada (Philippines, Singapore) (65) 6231 2842

### Transport & Infrastructure

Anderson Chow (Asia, China) (852) 2823 4773  
 Jonathan Windham (Asia, China) (852) 2823 5417  
 Tim Bacchus (Asia, China) (852) 2823 3586  
 Wei Sim (China, Hong Kong) (852) 2823 3598  
 Eunsook Kwak (Korea) (822) 3705 8644  
 Sunaina Dhanuka (Malaysia) (603) 2059 8993

### Utilities

Carol Cao (China, Hong Kong) (852) 2823 4075  
 Adam Worthington (Indonesia) (6221) 515 7338  
 Prem Jearajasingam (Malaysia) (603) 2059 8989  
 Dante Tinga (Philippines) (632) 857 0815

### Commodities

Jim Lennon (4420) 7065 2014  
 Adam Rowley (4420) 7065 2013  
 Jonathan Butcher (4420) 7065 5938  
 Max Layton (4420) 7065 2000  
 Bonnie Liu (8621) 2412 9008  
 Henry Liu (8621) 2412 9005

### Data Services

Andrea Clohessy (Asia) (852) 2823 4076  
 Henry Hon (Asia) (852) 2823 3593  
 Max Choi (Asia) (852) 2823 5479

### Economics

Roland Randall (Asean) (852) 2823 3572  
 Bill Belchere (Asia) (852) 2823 4636  
 Eli Polatinsky (Asia) (852) 2823 4074  
 Richard Gibbs (Australia) (612) 8232 3935  
 Paul Cavey (China) (852) 2823 3570  
 Richard Jerram (Japan) (813) 3512 7855

### Quantitative

Martin Emery (Asia) (852) 2823 3582  
 Viking Kwok (Asia) (852) 2823 4735  
 George Platt (Australia) (612) 8232 6539  
 Raelene de Souza (Australia) (612) 8232 8388

### Strategy/Country

Tim Rocks (Asia) (852) 2823 3585  
 Daniel McCormack (Asia) (852) 2823 4073  
 Desh Peramunetilleke (Asia) (852) 2823 3564  
 Stewart Ferns (Asia) (852) 2823 4068  
 Jake Lynch (China) (8621) 2412 9007  
 Seshadri Sen (India) (9122) 6653 3053  
 Kenneth Yap (Indonesia) (6221) 515 7343  
 Chris Hunt (Japan) (813) 3512 7878  
 Peter Eadon-Clarke (Japan) (813) 3512 7850  
 Eugene Ha (Korea) (822) 3705 8643  
 Uday Jayaram (Malaysia) (603) 2059 8988  
 Edward Ong (Malaysia) (603) 2059 8982  
 Alex Pomento (Philippines) (632) 857 0899  
 Tuck Yin Soong (ASEAN, Singapore) (65) 6231 2838  
 Alastair Macdonald (Thailand) (662) 694 7741

### Find our research at

Macquarie: [www.macquarie.com.au/research](http://www.macquarie.com.au/research)  
 Thomson: [www.thomson.com/financial](http://www.thomson.com/financial)  
 Reuters: [www.rbr.reuters.com](http://www.rbr.reuters.com)  
 Bloomberg: MAC GO  
 Factset: <http://www.factset.com/home.aspx>  
 Email [macresearch@macquarie.com](mailto:macresearch@macquarie.com) for access

## Sales

### Regional Heads of Sales

Peter Slater (Boston) (1 617) 217 2103  
 Michelle Paisley (China, Hong Kong) (852) 2823 3516  
 Ulrike Pollak-Tsutsumi (Frankfurt) (49) 69 7593 8747  
 Thomas Renz (Geneva) (41) 22 818 7712  
 Ajay Bhatia (India) (9122) 6653 3200  
 Stuart Smythe (India) (9122) 6653 3200  
 Chris Gray (Indonesia) (6221) 515 7304  
 K.Y. Nam (Korea) (822) 3705 8607  
 Derek Wilson (London) (N Asia) (44) 20 7065 5856  
 Julien Roux (London) (44) 20 7065 5887  
 Lena Yong (Malaysia) (603) 2059 8888  
 Ismael Pili (Philippines) (65) 6231 2840  
 Greg Norton-Kidd (New York) (1 212) 231 2527  
 Luke Sullivan (New York) (1 212) 231 2507

### Regional Heads of Sales cont'd

Mark Lawrence (New York) (1 212) 231 2516  
 Sheila Schroeder (San Francisco) (1 415) 835 1235  
 Giles Heyring (Singapore) (65) 6231 2888  
 Mark Duncan (Taiwan) (8862) 2734 7510  
 Angus Kent (Thailand) (662) 694 7601  
 Dominic Henderson (Tokyo) (813) 3512 7820  
 Nick Cant (Tokyo) (813) 3512 7821  
 Charles Nelson (UK/Europe) (44) 20 7065 2032  
 Rob Fabbro (UK/Europe) (44) 20 7065 2031

### Sales Trading

Adam Zaki (North Asia) (852) 2823 3528  
 Duncan Rutherford (ASEAN, India) (65) 6231 2888  
 Mona Lee (Hong Kong) (852) 2823 3519

### Sales Trading cont'd

Stuart Goddard (Europe) (44) 20 7065 2033  
 Brendan Rake (India) (9122) 6653 3204  
 Edward Robinson (London) (44) 20 7065 5883  
 Robert Rismam (New York) (1 212) 231 2555  
 Isaac Huang (Taiwan) (8862) 2734 7582  
 Jon Omori (Tokyo) (813) 3512 7838

### Alternative Strategies

Convertibles - Roland Sharman (852) 2823 4628  
 Depository Receipts - Robert Ansell (852) 2823 4688  
 Derivatives - Tim Connolly (852) 2249 3380  
 Futures - Tim Smith (852) 2823 4637  
 Hedge Fund Sales - Darin Lester (852) 2823 4736  
 Structured Products - Andrew Terlich (852) 2249 3225